Clinical Trial Update: A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating dexmethylphenidate extended-release for attention-deficit/hyperactivity disorder in children aged 6 to 12 has completed and results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dexmethylphenidate Extended Release (dexmethylphenidate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED | Results posted: 2009-03-30